A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF mutant advanced melanoma (INTERIM).

Dayimu, Alimu; Gupta, Avinash; Matin, Rubeta N; Nobes, Jenny; Board, Ruth; Payne, Miranda; Rao, Ankit; Fusi, Alberto; Danson, Sarah; Eccles, Bryony; Carser, Judith; Brown, Ciara O'Hanlon; Steven, Neil; Bhattacharyya, Madhumita; Brown, Ewan; Gonzalez, Michael; Highley, Martin; Pickering, Lisa; Kumar, Satish; Waterston, Ashita; Burghel, George; Demain, Leigh; Baker, Eleanor; Wulff, Jerome; Qian, Wendi; Twelves, Sophie; Middleton, Mark; Corrie, Pippa

Name:

Publisher version

Abstract

BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen.

Citation

McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, Butt NM, Cargo C, Cross NCP, Francis S, Frewin R, Garg M, Godfrey AL, Green A, Khan A, Knapper S, Lambert J, McGregor A, McMullin MF, Nangalia J, Neelakantan P, Woodley C, Mead A, Somervaille TCP, Harrison CN; BSH Committee. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol. 2024 Jan;204(1):136-150. doi: 10.1111/bjh.19186. Epub 2023 Dec 1

Type

Article